Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells

Journal of Medicinal Chemistry

Volumn 57, Issue 11, 2014, Pages 4569-4583

  Maximov, Philipp Y ^a   Fernandes, Daphne J ^a   McDaniel, Russell E ^a   Myers, Cynthia B ^b   Curpan, Ramona F ^c   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ENDOXIFEN; ESTROGEN RECEPTOR; PROLACTIN;

ANIMAL CELL; ARTICLE; CELL DIVISION; CONFORMATION; CONTROLLED STUDY; DRUG SYNTHESIS; ESTROGEN ACTIVITY; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ISOMER; ISOMERIZATION; MCF 7 CELL LINE; MOLECULAR MODEL; NONHUMAN; PROLACTIN SYNTHESIS; RAT; RECEPTOR DOWN REGULATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOHEPTANES; ESTROGEN RECEPTOR MODULATORS; HUMANS; MOLECULAR DOCKING SIMULATION; RATS; RECEPTORS, ESTROGEN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84902436626     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500569h     Document Type: Article

References (48)

1. Maximov, P. Y.; McDaniel, R. E.; Jordan, V. C. Tamoxifen: Pioneering Medicine in Breast Cancer; Springer: Basel, Switzerland, 2013.
2. Davies, C.; Godwin, J.; Gray, R.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; Pan, H. C.; Taylor, C.; Wang, Y. C.; Dowsett, M.; Ingle, J.; Peto, R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 2011, 378, 771-784
3. Davies, C.; Pan, H.; Godwin, J.; Gray, R.; Arriagada, R.; Raina, V.; Abraham, M.; Medeiros Alencar, V. H.; Badran, A.; Bonfill, X.; Bradbury, J.; Clarke, M.; Collins, R.; Davis, S. R.; Delmestri, A.; Forbes, J. F.; Haddad, P.; Hou, M. F.; Inbar, M.; Khaled, H.; Kielanowska, J.; Kwan, W. H.; Mathew, B. S.; Mittra, I.; Muller, B.; Nicolucci, A.; Peralta, O.; Pernas, F.; Petruzelka, L.; Pienkowski, T.; Radhika, R.; Rajan, B.; Rubach, M. T.; Tort, S.; Urrutia, G.; Valentini, M.; Wang, Y.; Peto, R. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 2013, 381, 805-816
4. Fisher, B.; Costantino, J. P.; Wickerham, D. L.; Cecchini, R. S.; Cronin, W. M.; Robidoux, A.; Bevers, T. B.; Kavanah, M. T.; Atkins, J. N.; Margolese, R. G.; Runowicz, C. D.; James, J. M.; Ford, L. G.; Wolmark, N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 2005, 97, 1652-1662 (Pubitemid 41672231)
5. Harper, M. J.; Walpole, A. L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes Nature 1966, 212, 87
6. Allen, K. E.; Clark, E. R.; Jordan, V. C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships Br. J. Pharmacol. 1980, 71, 83-91 (Pubitemid 11167766)
7. Jordan, V. C.; Collins, M. M.; Rowsby, L.; Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity J. Endocrinol. 1977, 75, 305-316 (Pubitemid 8219148)
8. Lien, E. A.; Solheim, E.; Kvinnsland, S.; Ueland, P. M. Identification of 4-hydroxy- N -desmethyltamoxifen as a metabolite of tamoxifen in human bile Cancer Res. 1988, 48, 2304-2308
9. Lien, E. A.; Solheim, E.; Lea, O. A.; Lundgren, S.; Kvinnsland, S.; Ueland, P. M. Distribution of 4-hydroxy- N -desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment Cancer Res. 1989, 49, 2175-2183 (Pubitemid 19106533)
10. Borgna, J. L.; Rochefort, H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues J. Biol. Chem. 1981, 256, 859-868 (Pubitemid 11103040)
11. Johnson, M. D.; Zuo, H.; Lee, K. H.; Trebley, J. P.; Rae, J. M.; Weatherman, R. V.; Desta, Z.; Flockhart, D. A.; Skaar, T. C. Pharmacological characterization of 4-hydroxy- N -desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res. Treat. 2004, 85, 151-159 (Pubitemid 38987269)
12. Lim, Y. C.; Desta, Z.; Flockhart, D. A.; Skaar, T. C. Endoxifen (4-hydroxy- N -desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother. Pharmacol. 2005, 55, 471-478 (Pubitemid 40568978)
13. Lim, Y. C.; Li, L.; Desta, Z.; Zhao, Q.; Rae, J. M.; Flockhart, D. A.; Skaar, T. C. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells J. Pharmacol. Exp. Ther. 2006, 318, 503-512 (Pubitemid 44061223)
14. Lieberman, M. E.; Gorski, J.; Jordan, V. C. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro J. Biol. Chem. 1983, 258, 4741-4745 (Pubitemid 13096361)
15. Jordan, V. C.; Haldemann, B.; Allen, K. E. Geometric isomers of substituted triphenylethylenes and antiestrogen action Endocrinology 1981, 108, 1353-1361 (Pubitemid 11079158)
16. Jordan, V. C.; Koch, R.; Langan, S.; McCague, R. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro Endocrinology 1988, 122, 1449-1454 (Pubitemid 18091976)
17. McCague, R.; Leclercq, G.; Jordan, V. C. Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes J. Med. Chem. 1988, 31, 1285-1290
18. Maximov, P. Y.; Myers, C. B.; Curpan, R. F.; Lewis-Wambi, J. S.; Jordan, V. C. Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen J. Med. Chem. 2010, 53, 3273-3283
19. Lal, B.; Khanna, J. M.; Anand, N. Phenethylamine in a rigid framework. 2,3-Substituted cis- and trans-6-amino-6,7,8,9-tetrahydro-5 H -benzocyclohepten-5-ols J. Med. Chem. 1972, 15, 23-27
20. Kahn, A. M.; Proctor, G. R.; Rees, L. Novel aromatic systems. Part IV. Synthesis and dehydrogenation of 4′-hydroxy-1,2-benzocycloheptatrienes J. Chem. Soc. 1966, 990-994
21. Jarman, M.; McCague, R. Heptafluoro- p -tolyl and tetrafluoro-4-pyridyl as novel and selective protecting groups for phenolic and alcoholic functions: synthesis and cleavage of perfluoroaryl ethers of steroids J. Chem. Res., Synop. 1985, 114-115
22. Fauq, A. H.; Maharvi, G. M.; Sinha, D. A convenient synthesis of (Z)-4-hydroxy- N -desmethyltamoxifen (endoxifen) Bioorg. Med. Chem. Lett. 2010, 20, 3036-3038
23. Stearns, V.; Johnson, M. D.; Rae, J. M.; Morocho, A.; Novielli, A.; Bhargava, P.; Hayes, D. F.; Desta, Z.; Flockhart, D. A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J. Natl. Cancer Inst. 2003, 95, 1758-1764 (Pubitemid 38008898)
24. Murahashi, S. I.; Naota, T.; Miyaguchi, N.; Nakato, T. Ruthenium-catalyzed oxidation of tertiary-amines with hydrogen-peroxide in the presence of methanol Tetrahedron Lett. 1992, 33, 6991-6994
25. Lee, H. W.; Ahn, J. B.; Lee, J. H.; Kang, S. K.; Ahn, S. K.; Ha, D. C. Selective N-demethylation of tertiary aminofumagillols with selenium dioxide via a non-classical Polonovski type reaction Heterocycles 2006, 68, 915-932
26. Murdter, T. E.; Schroth, W.; Bacchus-Gerybadze, L.; Winter, S.; Heinkele, G.; Simon, W.; Fasching, P. A.; Fehm, T.; Eichelbaum, M.; Schwab, M.; Brauch, H. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma Clin. Pharmacol. Ther. 2011, 89, 708-717
27. Jordan, V. C.; Fritz, N. F.; Tormey, D. C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer Cancer Res. 1987, 47, 624-630 (Pubitemid 17009636)
28. Ravdin, P. M.; Fritz, N. F.; Tormey, D. C.; Jordan, V. C. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen Cancer Res. 1988, 48, 1026-1029 (Pubitemid 18061906)
29. Warnmark, A.; Treuter, E.; Gustafsson, J. A.; Hubbard, R. E.; Brzozowski, A. M.; Pike, A. C. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha J. Biol. Chem. 2002, 277, 21862-21868 (Pubitemid 34959959)
30. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 1998, 95, 927-937 (Pubitemid 29019045)
31. Rajan, S. S.; Kim, Y.; Vanek, K.; Joachimiak, A.; Jordan, C.; Greene, G. L., Crystal structure of human estrogen receptor alpha LBD in complex with GRIP peptide and two ismoers of ethoxy triphenylethylene. Manuscript to be published.
32. Renaud, J.; Bischoff, S. F.; Buhl, T.; Floersheim, P.; Fournier, B.; Halleux, C.; Kallen, J.; Keller, H.; Schlaeppi, J. M.; Stark, W. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands J. Med. Chem. 2003, 46, 2945-2957 (Pubitemid 36775919)
33. Vajdos, F. F.; Hoth, L. R.; Geoghegan, K. F.; Simons, S. P.; LeMotte, P. K.; Danley, D. E.; Ammirati, M. J.; Pandit, J. The 2.0 Å crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene Protein Sci. 2007, 16, 897-905 (Pubitemid 46683194)
34. Murphy, C. S.; Langan-Fahey, S. M.; McCague, R.; Jordan, V. C. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro Mol. Pharmacol. 1990, 38, 737-743
35. Jordan, V. C.; Lieberman, M. E. Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure Mol. Pharmacol. 1984, 26, 279-285 (Pubitemid 15157514)
36. Jordan, V. C.; Lieberman, M. E.; Cormier, E.; Koch, R.; Bagley, J. R.; Ruenitz, P. C. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro Mol. Pharmacol. 1984, 26, 272-278 (Pubitemid 15157513)
37. Jordan, V. C.; Koch, R.; Mittal, S.; Schneider, M. R. Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro Br. J. Pharmacol. 1986, 87, 217-223 (Pubitemid 16165905)
38. Murphy, C. S.; Parker, C. J.; McCague, R.; Jordan, V. C. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity Mol. Pharmacol. 1991, 39, 421-428
39. Lonard, D. M.; Nawaz, Z.; Smith, C. L.; O'Malley, B. W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation Mol. Cell 2000, 5, 939-948
40. Obiorah, I. E.; Sengupta, S.; Curpan, R.; Jordan, V. C. Defining the conformation of the estrogen receptor complex that controls estrogen induced apoptosis in breast cancer Mol. Pharmacol. 2014, 85, 789-799
41. Nicholson, R. I.; Gee, J. M.; Manning, D. L.; Wakeling, A. E.; Montano, M. M.; Katzenellenbogen, B. S. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer Ann. N.Y. Acad. Sci. 1995, 761, 148-163
42. Wu, X.; Hawse, J. R.; Subramaniam, M.; Goetz, M. P.; Ingle, J. N.; Spelsberg, T. C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells Cancer Res. 2009, 69, 1722-1727
43. Liu, H.; Lee, E. S.; Deb Los Reyes, A.; Zapf, J. W.; Jordan, V. C. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex Cancer Res. 2001, 61, 3632-3639 (Pubitemid 32694973)
44. Jordan, V. C. The 38th David A. Karnofsky Lecture: The paradoxical actions of estrogen in breast cancer-survival or death? J. Clin. Oncol. 2008, 26, 3073-3082
45. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 (Pubitemid 30047768)
46. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749 (Pubitemid 38380917)
47. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J. Med. Chem. 2004, 47, 1750-1759 (Pubitemid 38380918)
48. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196 (Pubitemid 44595196)